Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Christy Taylor

Nurse Practitioner Idaho Falls, ID Nurse Practitioner

NPI 1386167492 CMS profile 10798953

3385 Potomac Way, Idaho Falls, ID 83404

Open in the dashboard

General payments

$5,634

265 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christy Taylor of Idaho Falls, ID is reported in the CMS Open Payments database as having received $5,634 across 265 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $898 53
2024 General $2,648 52
2023 General $714 55
2022 General $616 47
2021 General $759 58

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christy Taylor
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Christy Taylor were reported at $898. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Christy Taylor Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $759 $135 $40–$426 $132
2022 $616 $152 $48–$470 $149
2023 $714 $166 $54–$529 $160
2024 $2,648 $173 $55–$556 $164
2025 $898 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Nalu Medical, Inc. $2,335 35 payments
  2. AbbVie, Inc. $863 48 payments
  3. Medtronic, Inc. $833 68 payments
  4. Abbott Laboratories $522 36 payments
  5. Boston Scientific Corporation $458 44 payments
  6. Nevro Corp. $117 3 payments
  7. Scilex Pharmaceuticals Inc. $85 6 payments
  8. Teva Pharmaceuticals USA, Inc. $72 4 payments
  9. Merz Pharmaceuticals, LLC $72 3 payments
  10. Pfizer Inc. $57 4 payments
  11. Other $218 14 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,249 262 payments
  2. Travel and Lodging $1,385 3 payments
Products named General payments · program years 2021–2025
  1. Nalu Neurostimulation System $2,335 35 payments
  2. QULIPTA $688 40 payments
  3. UBRELVY $496 27 payments
  4. PROCLAIM $325 17 payments
  5. SYNCHROMEDII $315 19 payments
  6. INCEPTIV $189 15 payments
  7. INTELLIS ADAPTIVESTIM $135 18 payments
  8. Omnia $117 3 payments
  9. WaveWriter Alpha Prime 16 $112 14 payments
  10. Proclaim IPG $112 12 payments
  11. Other $1,103 79 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

3,396

Median for Nurse Practitioner: 389

Drug cost

$228,915

Median for Nurse Practitioner: $21,885

Branded share of claims

41.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nurtec Odt Rimegepant Sulfate Brand 25 $43,037
Buprenorphine Generic 120 $42,066
Belbuca Buprenorphine Hcl Brand 64 $22,747
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 638 $19,022
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 31 $13,118
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 410 $10,925
Nucynta Tapentadol Hcl Brand 12 $9,967
Movantik Naloxegol Oxalate Brand 18 $7,169
Oxycodone Hcl Generic 287 $7,163
Celecoxib Generic 95 $5,538

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$35,570

Medicare's payments for the services billed

Medicare patients

166

Average age 71

Services billed

781

104 women, 62 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 39%
Depression 37%
Chronic kidney disease 29%
Ischemic heart disease 22%
Heart failure 20%
Osteoporosis 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $122
$122 — —
QULIPTA
  • AbbVie, Inc. $122
$122 — —
Xeomin
  • Merz Pharmaceuticals, LLC $52
$52 — —
ZEPOSIA
  • Celgene Corporation $33
$33 — —
VRAYLAR
  • AbbVie, Inc. $29
$29 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

265 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Idaho

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record